Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Market Checkup: Johnson & Johnson's Second Quarter

The Motley Fool's health-care show Market Checkup for August 13, 2013.


Market Checkup: Merck

The Motley Fool's health-care show with David Williamson and Max Macaluso.


What Are the Main Risks and Opportunities in Merck's Cholesterol Drug Franchise?

A look at Merck's portfolio of lipid-lowering drugs.


Can This Struggling Drugmaker Overcome Generic Statins?

AstraZeneca's leading drug Crestor facing competition from a number of cheaper generic drugs.


FDA vs. Cheerios: The Weirdest Battle in History?

The FDA's warning letter to General Mills in 2009 helped the agency ensure that foods wouldn't be promoted for therapeutic purposes.

Market Checkup: High Cholesterol

Our weekly healthcare show "Market Checkup" takes a look at the major pharmaceutical players in the high cholesterol space.


What's Behind St. Jude Medical's 5% Pop?

Shares of St. Jude Medical climbed today after the company released Q2 results.


Merck's Progress in the Fight Against Alzheimer's

Merck is hoping for more positive results from its experimental Alzheimer's disease drug.


Will Novartis' Earnings Impress Wall Street?

What investors need to watch in Novartis' Q2 results.


Will Abbott's Earnings Wow Wall Street?

What should investors watch in tomorrow's earnings report?

Will Big Pharma Dominate the Obesity Space?

Novo Nordisk and AstraZeneca might be the first "big pharma" companies to market drugs for the treatment of obesity.


Market Checkup: Obesity

In this edition of "Market Checkup," our health-care analysts discuss emerging treatments for obesity.


Is This Billion-Dollar Diabetes Drug Class Doomed?

A look at Merck's most important drugs.


Ask a Fool: What Will Belviq's Launch Do for Arena?

Could Arena Pharmaceuticals' new obesity drug Belviq be facing headwinds right from the start?


Ask a Fool: What's Up With MAKO Surgical?

What does a Fool think of MAKO Surgical stock today?

The Market Checkup: Type 2 Diabetes

What should investors know about the leading drugmakers in the type 2 diabetes space?


Down 30%: What Caused Idenix's Crash?

Why did shares of Idenix crash today?


Sarepta Pops on More Positive Data

What was behind this development-stage biotech's pop?


Will Amarin's Fish Oil Drug Slip Past the FDA a Second Time?

The advisory committee meeting date for the ANCHOR indication is now set.


Does Restless Legs Syndrome Really Shorten Life Span?

A new study suggests a link between this neurological disorder and mortality rates in men.